Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10363298-B2
Publication Date
2019-07-30
Expiration Date
Abstract
The present invention is based on the finding that in addition to interfering with or blocking, preventing and/or inhibiting the interaction between a pathogen and, for example, a sialic acid containing cell surface receptor, certain sialic acid binding molecules have immunomodulatory properties. The invention provides methods and uses which exploit sialic acid binding molecules in the treatment and/or prevention of disease by modulation and/or priming of the host immune response.
Core Innovation
The invention provides sialic acid-binding molecules/proteins, including multivalent carbohydrate-binding modules and engineered multivalent forms such as Sp2CBMTD and Vc2CBMTD, for modulating or priming host immune responses. These sialic acid-binding molecules/proteins enhance cytokine/chemokine expression and immune cell recruitment as part of immune modulation/priming.
The disclosed compositions also function in masking sialic acid receptors to prevent pathogen binding, in addition to immune modulation. The multivalent carbohydrate-binding modules are described with engineered multivalent forms, including those comprising an oligomerisation/trimerisation domain.
The document further describes claimed uses for prophylaxis and post-infection treatment across microbial pathogens, with emphasis on respiratory infections and respiratory pathogens. The disclosure includes immune-related readouts such as cytokine changes, neutrophil recruitment, maintenance of adaptive responses, and protection in influenza challenge models including H1N1, H7N9, and H5N1.
Claims Coverage
The provided relevant claims indicate one independent claim focused on immune modulation/priming by multi-dose administration of Sp2CBMTD prior to infection or likely infection.
Multi-dose pre-infection immune modulation or priming with Sp2CBMTD
A method of modulating or priming an immune response in a subject by administering an immunomodulatory amount or quantity of Sp2CBMTD to a healthy subject in need thereof in more than one dose prior to an infection or a likely infection caused or contributed to by a pathogen.
The claim coverage centers on pre-infection immune modulation/priming in a healthy subject using more than one dose of Sp2CBMTD at an immunomodulatory amount or quantity.
Stated Advantages
Enhances cytokine/chemokine expression and immune cell recruitment (immune modulation/priming).
Provides protection in influenza challenge models with viral load reduction and cytokine changes.
Maintains adaptive antibody responses.
Supports neutrophil recruitment.
Prevents pathogen binding by masking sialic acid receptors.
Documented Applications
Prophylaxis and post-infection treatment across microbial pathogens, with emphasis on respiratory diseases/infections and respiratory pathogens.
Use in influenza challenge models involving H1N1, H7N9, and H5N1, with reported outcomes including protection and reductions in viral load.
Interested in licensing this patent?